Our results clearly demonstrated that CDK4/6 inhibitors plus endocrine therapy had a substantial positive impact on both PFS and OS in patients with HR+/HER2- breast cancer and had no heterogeneity compared with endocrine therapy alone. The gene discussed is CDK4; the disease is breast carcinoma.